AU2002220796A1 - Medicine based on anti-hyperglycaemic microcapsules with prolonged release - Google Patents

Medicine based on anti-hyperglycaemic microcapsules with prolonged release

Info

Publication number
AU2002220796A1
AU2002220796A1 AU2002220796A AU2079602A AU2002220796A1 AU 2002220796 A1 AU2002220796 A1 AU 2002220796A1 AU 2002220796 A AU2002220796 A AU 2002220796A AU 2079602 A AU2079602 A AU 2079602A AU 2002220796 A1 AU2002220796 A1 AU 2002220796A1
Authority
AU
Australia
Prior art keywords
hyperglycaemic
microcapsules
medicine
prolonged release
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220796A
Inventor
Catherine Castan
Remi Meyrueix
Gerard Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Technologies SA
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Publication of AU2002220796A1 publication Critical patent/AU2002220796A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine. The invention is applicable to the treatment of type II diabetes.
AU2002220796A 2000-11-17 2001-11-19 Medicine based on anti-hyperglycaemic microcapsules with prolonged release Abandoned AU2002220796A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR00/14876 2000-11-17
FR0014876 2000-11-17
FR0014876A FR2816840B1 (en) 2000-11-17 2000-11-17 MEDICINE BASED ON SUSTAINED RELEASE ANTI-HYPERCLYCEMIA MICROCAPSULES AND METHOD FOR PREPARING THE SAME
PCT/FR2001/003625 WO2002039984A2 (en) 2000-11-17 2001-11-19 Medicine based on anti-hyperglycaemic microcapsules with prolonged release

Publications (1)

Publication Number Publication Date
AU2002220796A1 true AU2002220796A1 (en) 2002-05-27

Family

ID=8856604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220796A Abandoned AU2002220796A1 (en) 2000-11-17 2001-11-19 Medicine based on anti-hyperglycaemic microcapsules with prolonged release

Country Status (13)

Country Link
US (1) US8197850B2 (en)
EP (1) EP1333816B1 (en)
JP (1) JP2004513913A (en)
CN (2) CN1853617A (en)
AT (1) ATE425745T1 (en)
AU (1) AU2002220796A1 (en)
BR (1) BR0115958A (en)
CA (1) CA2428782C (en)
DE (1) DE60138033D1 (en)
ES (1) ES2324205T3 (en)
FR (1) FR2816840B1 (en)
PT (1) PT1333816E (en)
WO (1) WO2002039984A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822834B1 (en) * 2001-04-02 2005-02-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF NANOPARTICLES BASED ON AMPHIPHILIC COPOLYMERS FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION
FR2825023B1 (en) 2001-05-23 2005-04-15 Flamel Tech Sa ANTIDIABETIC ORAL PHARMACEUTICAL FORM "ONE TAKEN PER DAY" INCLUDING BIGUANIDE AND AT LEAST ONE OTHER ACTIVE INGREDIENT
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2837100B1 (en) * 2002-03-18 2004-07-23 Flamel Tech Sa MODIFIED RELEASE MICROCAPSULE-BASED TABLETS
FR2843881B1 (en) * 2002-09-02 2006-06-02 Flamel Tech Sa ORAL PHARMACEUTICAL FORMULATION AS AQUEOUS SUSPENSION OF MICROCAPSULES FOR MODIFIED RELEASE OF ACTIVE (S) PRINCIPLE (S)
PT1492511E (en) 2002-04-09 2009-04-09 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
ES2314227T7 (en) 2002-04-09 2012-11-19 Flamel Technologies ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF A WATERPROOF SUSPENSION OF MICROCAPSULES THAT ALLOW THE MODIFIED RELEASE OF AMOXYLYCIN.
FR2842735B1 (en) * 2002-07-26 2006-01-06 Flamel Tech Sa MODIFIED RELEASE MICROCAPSULES OF LOW SOLUBLE ACTIVE PRINCIPLES FOR PER OS ADMINISTRATION
FR2842736B1 (en) * 2002-07-26 2005-07-22 Flamel Tech Sa ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF A PLURALITY OF MICROCAPSULES FOR PROLONGED RELEASE OF LOW SOLUBLE ACTIVE (S) PRINCIPLE (S)
FR2843117B1 (en) * 2002-07-30 2004-10-15 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY AT LEAST ONE HYDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
RU2005108577A (en) * 2002-09-28 2006-06-10 МакНЕЙЛ-ППС, ИНК. (US) DOSED FORMS WITH MODIFIED RELEASE
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
FR2860516B1 (en) * 2003-10-03 2006-01-13 Flamel Tech Sa TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2862536B1 (en) * 2003-11-21 2007-11-23 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
US8158703B2 (en) 2004-03-02 2012-04-17 Poly Coat Pty. Ltd. Paintable primer system
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
CN101602865B (en) * 2009-03-13 2011-08-31 王懋 Ethylcellulose mixed suspension liquid and preparation method and application thereof
CN102869349A (en) * 2010-03-09 2013-01-09 阿尔科米斯制药爱尔兰有限公司 Alcohol resistant enteric pharmaceutical compositions
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
WO2013077821A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Homogeneous biguanide composition
CN103637999B (en) * 2013-12-12 2014-12-03 南通联亚药业有限公司 Multilayer solid pharmaceutical dosage form
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
MX2016014320A (en) 2014-05-01 2017-05-23 Sun Pharmaceutical Ind Ltd Extended release suspension compositions.
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
MX2017001332A (en) 2014-07-30 2017-08-02 Sun Pharmaceutical Ind Ltd Dual-chamber pack.
EP3288539A4 (en) * 2015-05-01 2019-07-10 Sun Pharmaceutical Industries Ltd Extended release liquid compositions of metformin
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
FR3055800B1 (en) * 2016-09-15 2020-06-26 Unither Pharmaceuticals SOLID COMPOSITION WITH FAST INGESTION AND EASY SWALLOWING, IN THE FORM OF NON-AGGLOMERATED SOLID PARTICLES, COMPRISING TWO DIFFERENT TYPES OF PARTICLES
CA3092930A1 (en) * 2018-03-07 2019-09-12 Anabio Technologies Ltd. A composition for type ii diabetics and for use in providing sustained energy release over time

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (en) * 1977-08-27 1987-01-14 Bayer Ag ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE.
JPS6051189A (en) * 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
DE3543999A1 (en) * 1985-12-13 1987-06-19 Bayer Ag HIGH PURITY ACARBOSE
GB9104854D0 (en) * 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
ATE154241T1 (en) * 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd MICROPARTICLE SUMMARY FOR EXTENDED RELEASE AND PRODUCTION THE SAME
JP3277342B2 (en) * 1992-09-02 2002-04-22 武田薬品工業株式会社 Manufacturing method of sustained release microcapsules
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JPH08151322A (en) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd Oral sustained release agent
FR2725623A1 (en) * 1994-10-18 1996-04-19 Flamel Tech Sa MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION
IT1276130B1 (en) * 1995-11-14 1997-10-27 Gentili Ist Spa GLIBENCLAMIDE-METFORMIN ASSOCIATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND THEIR USE IN THE TREATMENT OF TYPE DIABETES MELLITUS
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
KR100620935B1 (en) * 1998-03-19 2006-09-13 브리스톨-마이어스스퀴브컴파니 Biphasic Controlled Release Delivery System for High Solubility Pharmaceuticals and Method
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
ES2206868T3 (en) * 1998-07-15 2004-05-16 Merck Sante TABLETS THAT UNDERSTAND A COMBINATION OF METFORMIN GLIBENCLAMIDE.
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
JP2000085159A (en) 1998-09-14 2000-03-28 Ricoh Co Ltd Image processing method
CA2351058A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
DE19860698A1 (en) 1998-12-30 2000-07-06 Hexal Ag New pharmaceutical composition
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
AR028299A1 (en) 1999-09-17 2003-05-07 Novartis Ag A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY.
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
WO2001032157A2 (en) 1999-11-03 2001-05-10 Bristol-Myers Squibb Company Pharmaceutical composition comprising a combination of metformin and glibenclamide
PT1616561E (en) * 1999-12-28 2008-07-09 Ajinomoto Kk Antidiabetic preparation for oral administration
FR2811571B1 (en) * 2000-07-11 2002-10-11 Flamel Tech Sa ORAL PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE AND SUSTAINED ABSORPTION OF AN ACTIVE INGREDIENT
FR2825023B1 (en) 2001-05-23 2005-04-15 Flamel Tech Sa ANTIDIABETIC ORAL PHARMACEUTICAL FORM "ONE TAKEN PER DAY" INCLUDING BIGUANIDE AND AT LEAST ONE OTHER ACTIVE INGREDIENT

Also Published As

Publication number Publication date
ATE425745T1 (en) 2009-04-15
CN1474687A (en) 2004-02-11
PT1333816E (en) 2009-06-23
FR2816840B1 (en) 2004-04-09
CA2428782C (en) 2013-01-08
JP2004513913A (en) 2004-05-13
BR0115958A (en) 2004-01-06
FR2816840A1 (en) 2002-05-24
EP1333816A2 (en) 2003-08-13
EP1333816B1 (en) 2009-03-18
ES2324205T3 (en) 2009-08-03
CN1853617A (en) 2006-11-01
WO2002039984A3 (en) 2002-07-11
WO2002039984A2 (en) 2002-05-23
US20040175424A1 (en) 2004-09-09
DE60138033D1 (en) 2009-04-30
CA2428782A1 (en) 2002-05-23
US8197850B2 (en) 2012-06-12

Similar Documents

Publication Publication Date Title
AU2002220796A1 (en) Medicine based on anti-hyperglycaemic microcapsules with prolonged release
Serrano et al. Riehl's melanosis: pigmented contact dermatitis caused by fragrances
AU740375B2 (en) Use of gastrointestinal lipase inhibitors
IE802676L (en) Sulfonyl ureas.
MY131810A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
MY125118A (en) Antidiabetic formulation and method
HUP0104303A2 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
CA2386690A1 (en) Pharmaceutical tramadol salts
ATE48598T1 (en) CERTAIN 3-(5-AMINOPENTYL)-AMINO-1-BENZAZEPINE-2-ONE-1-ALK N ACIDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR THERAPEUTIC USE.
DE58909793D1 (en) New benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds
NO307495B1 (en) Use of riluzole in the manufacture of medications for the treatment of Parkinson's disease and Parkinson's syndromes
EP0382066A3 (en) Use of dihydroliponic acid as an analgetic, antiphlogistic and/or cytoprotective agent
WO2003057380A3 (en) Compositions including ammonia oxidizing bacteria and methods of using same
HUP0204109A2 (en) Oral preparations for diabetes
WO2001032157A3 (en) Pharmaceutical composition comprising a combination of metformin and glibenclamide
NZ336001A (en) Sustained release formulation comprising nefazodone
IL158155A (en) Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
Jones et al. Photosensitive lichenoid eruption associated with demeclocycline
Hitselberger et al. Photosensitivity due to chlorpropamide
ATE104146T1 (en) DELAYED-RELEASE PREPARATION OF A HYDROCHLORIDE OF A BASIC DRUG.
WO2001093850B1 (en) Methods and compositions using sulodexide for the treatment of diabetic nephropathy
EE9600202A (en) Carbamazepine sustained release formulation
O'Malley et al. Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension
ATE66220T1 (en) SUBSTITUTED QUINOXALYL-IMIDAZOLIDINE-2,4-DIONES, PROCESS FOR THEIR PRODUCTION, THEIR USE AS MEDICINAL PRODUCTS AND PHARMACEUTICAL PREPARATIONS.
JPH0327313A (en) Compound containing a physio- logical dosage of vitamine a and various effective compo- nents with therapeutic activity